Catherine C. Turkel Sells 9,537 Shares of Novus Therapeutics Inc (NVUS) Stock

Novus Therapeutics Inc (NASDAQ:NVUS) President Catherine C. Turkel sold 9,537 shares of Novus Therapeutics stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $1.95, for a total value of $18,597.15. Following the completion of the transaction, the president now directly owns 90,576 shares of the company’s stock, valued at $176,623.20. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Novus Therapeutics stock traded up $0.02 during midday trading on Friday, reaching $1.73. The stock had a trading volume of 27,675 shares, compared to its average volume of 45,017. Novus Therapeutics Inc has a 12 month low of $1.52 and a 12 month high of $8.61. The firm has a market capitalization of $16.13 million, a price-to-earnings ratio of -1.11 and a beta of 3.32. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.18 and a quick ratio of 3.18.

Novus Therapeutics (NASDAQ:NVUS) last issued its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). On average, sell-side analysts expect that Novus Therapeutics Inc will post -1.61 EPS for the current year.

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in Novus Therapeutics by 73.5% in the 3rd quarter. Vanguard Group Inc. now owns 135,599 shares of the biopharmaceutical company’s stock valued at $633,000 after buying an additional 57,450 shares in the last quarter. National Asset Management Inc. increased its position in Novus Therapeutics by 167.2% in the 4th quarter. National Asset Management Inc. now owns 120,219 shares of the biopharmaceutical company’s stock valued at $193,000 after buying an additional 75,219 shares in the last quarter. Vanguard Group Inc increased its position in Novus Therapeutics by 73.5% in the 3rd quarter. Vanguard Group Inc now owns 135,599 shares of the biopharmaceutical company’s stock valued at $633,000 after buying an additional 57,450 shares in the last quarter. Renaissance Technologies LLC increased its position in Novus Therapeutics by 28.6% in the 3rd quarter. Renaissance Technologies LLC now owns 251,556 shares of the biopharmaceutical company’s stock valued at $1,175,000 after buying an additional 55,968 shares in the last quarter. Finally, Morgan Stanley increased its position in Novus Therapeutics by 5,676.8% in the 1st quarter. Morgan Stanley now owns 12,189 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 11,978 shares in the last quarter. 36.09% of the stock is owned by institutional investors and hedge funds.

NVUS has been the subject of several research analyst reports. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $10.00 price objective on shares of Novus Therapeutics in a research report on Wednesday, May 15th. ValuEngine raised Novus Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, February 25th. Finally, Zacks Investment Research raised Novus Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/24/catherine-c-turkel-sells-9537-shares-of-novus-therapeutics-inc-nvus-stock.html.

Novus Therapeutics Company Profile

Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection).

See Also: Market Perform

Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.